Skip to content
nuwiq-logo NUWIQ logo
Main Menu
  • Intended for US Healthcare Professionals Only
  • Visit Patients and Families Site
  • Important Safety Information
  • Full Prescribing Information
  • Contact Us
  • Search Close
  • About NUWIQ
    • What Is NUWIQ?
    • Human Cell Line
    • Manufacturing Process
    • Molecular Design Implications
  • Clinical Evidence
    • Safety & Efficacy
  • Dosing
    • Dosing
    • Personalized Prophylaxis
    • Reconstitution Video
  • Patient Support
    • Factor My Way™ Patient Support Program
    • Free Trial Program
    • NUWIQ Co-Pay Assistance
  • Connect
    • Find a Rep
  • Intended for US Healthcare Professionals Only
  • Visit Patients and Families Site

Site Map

Home » Site Map

Pages

  • Home
  • About NUWIQ
    • What is NUWIQ
    • Human Cell Line
    • Manufacturing Process
    • Molecular Design Implications
  • Clinical Evidence
    • Safety & Efficacy
  • Dosing
    • Personalized Prophylaxis
    • Reconstitution Video
  • Patient Support
    • Factor My Way™ Patient Support Program
    • NUWIQ Free Trial for Patients with Hemophilia A
    • NUWIQ Co-Pay Assistance
  • Connect
    • Find a Rep
  • Contact Us
    • Thank You
Indications and Important Safety Information for NUWIQ .

Please see NUWIQ  full Prescribing Information.  Instructions For Use

Indications and Important Safety Information for NUWIQ .

Please see NUWIQ  full Prescribing Information.  Instructions For Use

Indications and Usage

NUWIQ® is a recombinant antihemophilic factor [coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ® is not indicated for the treatment of von Willebrand Disease.

Contraindications

NUWIQ is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions

The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Please see NUWIQ  full Prescribing Information. Instructions For Use

Scroll Back to Top
Octapharma logo
  • Facebook
  • Home
  • Site Map
  • Terms of Use
  • Privacy Policy
  • California Required Statements
  • Contact Us
© 2021 Octapharma USA Inc. All Rights Reserved
  • About Octapharma
  • NUW-0324

FOR U.S. HEALTHCARE PROFESSIONALS ONLY

The information on this website has been specifically created for U.S. healthcare professionals (HCPs)

This website uses cookies and stores information on your computer. Some of them are essential to improve our website and your user experience. By using this website, you agree to the use of these cookies. Please check our privacy policy for more details.